1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Nectar Lifesciences Ltd.

Nectar Lifesciences Ltd.

10.28
INR
-0.48
(-4.46%)
0.68EPS
2.25BMarket Cap
Nectar Lifesciences Ltd.
NSE:NECLIFE
(National Stock Exchange of India)

Recent

price

10.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
47.06
58.11
72.45
73.03
73.26
74.72
73.29
83.66
124.09
105.52
68.82
74.41
67.94
75.09
- -
- -
0.24
Revenue per Share
4.65
3.26
3.82
2.77
2.95
2.42
2.47
2.33
2.12
1.42
-3.27
1.12
-1.08
0.22
-5.07
-13.4
-3.29
Basic EPS, GAAP
-6.96
-4.19
10.71
6.84
2.85
4.05
6.48
1.43
8.97
10.26
-0.44
3.12
4.62
8.71
5.6
-19.62
- -
Free Cash Flow per Basic Share
- -
0.1
0.1
0.1
0.1
0.12
0.12
0.06
0.06
0.06
0.05
- -
- -
- -
- -
- -
- -
Dividend per Share
32.16
34.98
38.69
41.34
40.22
42.54
44.89
47.21
49.28
50.66
47.36
48.51
47.47
47.68
42.63
29.97
- -
Book Value per Share
32.16
34.98
38.69
41.34
36.67
39.51
42.33
45.16
47.53
48.91
45.65
46.59
45.27
45.34
40.11
29.92
- -
Tangible Book Value per Share
224
224
224
224
224
224
224
224
224
224
224
224
224
224
224
219
211
Basic Weighted Avg Shares
10,554
13,033
16,248
16,378
16,429
16,757
16,437
18,763
27,829
23,664
15,433
16,688
15,237
16,841
- -
- -
50
Sales/Revenue/Turnover
18.34
14.5
13.18
12.49
11.59
10.84
9.88
9.18
7.23
6.73
4.02
6.09
-0.34
5.49
- -
- -
-1,740.53
Operating Margin (%)
461
607
759
842
766
574
623
643
633
608
603
570
591
607
624
228
5
Depreciation Expense
1,042
732
857
621
663
542
553
523
476
318
-733
250
-242
50
-1,137
-2,929
-694
Net Income, GAAP
13.48
14.3
25.28
20.64
21.82
15.02
17.92
16.61
19.08
15.16
- -
26.51
- -
72.66
34.98
- -
- -
Effective Tax Rate (%)
9.87
5.62
5.28
3.79
4.03
3.24
3.37
2.79
1.71
1.34
-4.75
1.5
-1.59
0.3
- -
- -
-1,384.56
Profit Margin (%)
1,412
1,453
1,062
1,113
2,128
2,245
2,172
3,513
3,691
3,673
514
3,510
3,403
3,110
2,160
2,229
- -
Working Capital
2,343
3,636
2,610
2,233
2,655
2,454
1,638
2,201
1,656
1,215
1,282
2,911
2,265
1,403
601
- -
- -
LT Debt
7,211
7,845
8,676
9,271
9,020
9,541
10,067
10,587
11,052
11,361
10,620
10,879
10,646
10,693
9,561
5,823
- -
Total Equity
13.36
10.32
8.91
9.15
8.38
8.22
7.66
7.34
8.05
6.88
- -
4.17
- -
1.44
-2.49
- -
- -
Return on Invested Capital (%)
13.43
9.67
9.18
7.48
7.48
6.85
6.97
6.46
5.9
5.59
- -
3.91
- -
1.67
-7.01
- -
- -
Return on Capital (%)
15.53
9.73
10.38
6.92
7.25
5.84
5.64
5.06
4.4
2.84
-6.67
2.33
-2.25
0.47
-11.23
-38.08
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
224
194
194
Market Capitalization
4,353
1,807
2,248

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,530
- -
Cash, Cash Equivalents & STI
- -
1,251
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
3
- -
Total Current Liabilities
- -
301
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.76%
-9.79%
-39.1%
Free Cash Flow
-73%
-230.15%
-441.35%
Net Income, GAAP
-304.58%
-533.93%
157.64%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3,588
57
- -
- -
- -
2026
- -
50
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.13
-0.01
0.35
-5.8
-5.07
2026
-2.82
-0.01
0.64
-3.38
-13.4
2027
-0.79
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Nectar Lifesciences Limited, incorporated in 1995 and headquartered in Chandigarh, India, manufactures, markets and distributes pharmaceutical products with a focus on active pharmaceutical ingredients, intermediates and finished dosage forms, particularly in the cephalosporin antibiotics segment; core offerings include APIs such as Cefixime, Cefuroxime Axetil (amorphous and crystalline), Cefotaxime Sodium and Ceftriaxone Sodium, alongside contract manufacturing of cephalosporin solid dosage forms like tablets, capsules, dry powder oral suspensions, granules and injectables; additional products encompass menthol and mint derivatives, empty hard gelatin capsules, rapid test kits for conditions including HIV, dengue, syphilis, pregnancy and troponin I, as well as anti-inflammatory drugs and cardiovascular medications. The company operates manufacturing facilities compliant with EUGMP guidelines and holding approvals from regulators including PMDA Japan, ANVISA Brazil and COFEPRIS Mexico, spanning over 242,000 square meters near Chandigarh in Punjab and Himachal Pradesh; it serves markets in over 45 countries with a strong export focus on anti-infectives and lifesciences products. In July 2025, Nectar Lifesciences signed a definitive Business Transfer Agreement to divest its core API and formulations business to Ceph Lifesciences Private Limited for INR 1,270 crore on a slump sale basis, alongside an Asset Purchase Agreement for its menthol business assets valued at INR 20 crore; these transactions, approved by the board and pending shareholder and regulatory nods with expected completion by September 20, 2025, form part of a strategic restructuring to streamline operations, reduce debt, pursue new growth segments and enhance shareholder value.